Shionogi

#Infectious Disease #Neurology #Pain #Women's Health

Discovery-based pharmaceutical company (Shionogi & Co., TYO:4507, Osaka, Japan, founded 1878) with US subsidiary marketing Fetroja (MDR Gram-negative antibiotic), Radicava ORS (ALS), and Xocova (COVID-19 antiviral).

Company Info

Sector:Small Molecule Pharma

Headquarters:Osaka, Japan

Founded:1878

Website:www.shionogi.com/us/en/

Upcoming Milestones & Key Dates

2026-09-10

Clinical Data

Stroke drug mid-stage failure reported

Clinical Development Pipeline

Fetroja (cefiderocol)

Target: Siderophore cephalosporin

MDR Gram-negative infections

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Radicava ORS (edaravone)

Target: Free radical scavenger

ALS

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Xocova (ensitrelvir)

Target: 3CL protease

COVID-19

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Isao Teshirogi

Global CEO, Shionogi & Co.

Nathan McCutcheon

President & CEO, Shionogi Inc. (US)

Margaret Borys

EVP & Chief Commercial Officer (US)

Careers & Job Openings

See all open roles

Various

United States

Apply Now →